JPMorgan Chase & Co. Acquires 193,124 Shares of HilleVax, Inc. (NASDAQ:HLVX)

JPMorgan Chase & Co. boosted its holdings in HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 1,376.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 207,151 shares of the company's stock after acquiring an additional 193,124 shares during the period. JPMorgan Chase & Co. owned about 0.42% of HilleVax worth $429,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of HilleVax by 81.7% in the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after acquiring an additional 35,546 shares in the last quarter. Barclays PLC grew its position in HilleVax by 255.6% in the 3rd quarter. Barclays PLC now owns 42,033 shares of the company's stock worth $74,000 after purchasing an additional 30,213 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after buying an additional 6,916 shares in the last quarter. Ieq Capital LLC grew its position in HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after acquiring an additional 9,344 shares during the period. Finally, Intech Investment Management LLC bought a new stake in HilleVax during the 4th quarter worth approximately $26,000. 86.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, HilleVax presently has a consensus rating of "Hold" and a consensus target price of $3.00.

HilleVax Stock Down 2.0 %

HilleVax stock traded down $0.04 during trading on Monday, hitting $1.92. The stock had a trading volume of 221,424 shares, compared to its average volume of 447,183. The stock has a market cap of $96.27 million, a price-to-earnings ratio of -0.62 and a beta of 0.86. The stock's 50 day moving average is $1.70 and its two-hundred day moving average is $1.84. HilleVax, Inc. has a 1 year low of $1.34 and a 1 year high of $16.31.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). As a group, equities research analysts anticipate that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.